Phase II trials of combined BRAF and MEK inhibition in patients with previously treated and untreated NSCLC achieved overall response rates of 63% and 64% and median response durations of 9.7 and 10.4 months, respectively.3, 4. Here, MAP2K7 is linked to non-small cell lung carcinoma.